Journal of Dental Rehabilitation and Applied Science (구강회복응용과학지)

Korean Academy of Stomatognathic Function and Occlusion (대한턱관절교합학회)
권호 표지
DOI QR코드

DOI QR Code

The prevention of mortality after botulinum toxin injection in oral maxillofacial region

구강 악안면 영역에서 보툴리눔 독소 주사 후 사망 부작용의 예방

  • Lee, Won-Kang (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University) ;
  • Choi, Young-Chan (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University) ;
  • Choi, Moon-Jong (Sarangmaeul Psychiatric Clinic) ;
  • Kim, Seong-Taek (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University)
  • 이원강 (연세대학교 치과대학 구강내과학교실) ;
  • 최영찬 (연세대학교 치과대학 구강내과학교실) ;
  • 최문종 (사랑마을 정신과의원) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Received : 2014.07.30
  • Accepted : 2014.08.20
  • Published : 2014.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Botulinum toxin (BoNT) has been used for a wide spectrum of therapeutic and cosmetic indications, and the range of indications is continually increased. Though BoNT is a powerful poison, the fact that not only the effect but also the adverse effect of it fader about 6 months after injection makes clinicians to neglect its dangerous property in clinical application. But Many reports about the adverse effects including death of BoNT injection have been reported, the FDA edited in additional warnings about hospitalizations and deaths. In this study, we intended to look through the metabolic process in human body, possible adverse effect, matters to be attended in application, and cases reports about deaths of BoNT by reviewing the previous studies.

보툴리눔 독소는 여러 영역에서 치료적 목적으로 사용되어 왔으며, 그 사용량과 적용범위가 점차 커지는 추세이다. 보툴리눔 독소가 강력한 독성 물질임에도 불구하고, 그 효과가 6개월이면 사라지는 가역적 치료방법이라는 인식이 강해서, 부작용이나 사용시 주의사항을 중요하게 생각하지 않는 경향이 있었다. 하지만 미국에서 부작용으로 사망하는 사례가 발생하여, 사용시 사망에 대한 주의사항이 추가되었다. 이에 본 종설은 보툴리눔 독소가 인체 내에서 대사되는 과정과, 발생 가능한 부작용, 사용시 유의사항, 사망 부작용 사례 등에 대해 지금까지 보고된 문헌들을 토대로 자세히 검토하고자 한다.

Keywords

References

  1. Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013;68:40-59. https://doi.org/10.1016/j.toxicon.2013.02.014
  2. Lamanna C. The most poisonous poison. Science 1959;130:763-72. https://doi.org/10.1126/science.130.3378.763
  3. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93. https://doi.org/10.1146/annurev.pharmtox.44.101802.121554
  4. Elias M, Al-Saleem FH, Ancharski DM, Singh A, Nasser Z, Olson RM, Simpson LL. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 2011;336:605-12. https://doi.org/10.1124/jpet.110.175018
  5. Ravichandran E, Gong Y, Al-Saleem FH, Ancharski DM, Joshi SG, Simpson LL. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006;318:1343-51. https://doi.org/10.1124/jpet.106.104661
  6. Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, Simpson LL. The role of systemic handling in the pathophysiologic action of botulinum toxin. J Pharmacol Exp Ther 2008;326:856-63. https://doi.org/10.1124/jpet.108.136242
  7. Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 2011;338:503-17. https://doi.org/10.1124/jpet.111.180653
  8. Sheth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, Doerr F, Juliao P, Gonzalez G, Burnett C, Drenzek C, Shuler C, Austin J, Ellis A, Maslanka S, Sobel J. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008;47:1245-51. https://doi.org/10.1086/592574
  9. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003;10:13-8. https://doi.org/10.1038/nsb879
  10. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007;44:1029-41. https://doi.org/10.1016/j.molimm.2006.03.011
  11. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102. https://doi.org/10.1006/exnr.1997.6580
  12. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32:213-8. https://doi.org/10.1097/WNF.0b013e3181914d0a
  13. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm 2013;120:275-90. https://doi.org/10.1007/s00702-012-0893-9
  14. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic case. J Am Acad Dermatol 2005;53:407-15. https://doi.org/10.1016/j.jaad.2005.06.011